Compare Cell Therapeutics vs Dynavax Technologies Corporation
Customers evaluate the quality of Cell Therapeutics's products using the following success metrics.
Overview
Cell Therapeutics is 33 yrs old and is based in United States.
CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In the company's pursuit of making cancer more treatable, they are developing a diversified portfolio of oncology products focused on identifying and developing new, less toxic, and more effective ways to treat cancer.
Dynavax Technologies Corporation is 28 yrs old and is based in United States.
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Demo Video
Leadership
Craig W. Philips (President)
Lawrence M Lichtenstein (Founder)
Funding
Investors
EW Healthcare Partners, Icahn Enterprises
InterWest Partners, Scale Venture Partners
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Cell Therapeutics has not claimed their profile.
Work for Cell Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Cell Therapeutics?
Claim your profile now.
Information not available because Dynavax Technologies Corporation has not claimed their profile.
Work for Dynavax Technologies Corporation? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Dynavax Technologies Corporation?
Claim your profile now.